Mark Garnier Portrait

Mark Garnier

Conservative - Wyre Forest

Regulatory Reform
2nd Mar 2020 - 20th May 2021
European Statutory Instruments Committee
10th Feb 2020 - 14th Sep 2020
Parliamentary Under-Secretary (Department for International Trade)
17th Jul 2016 - 9th Jan 2018
Finance Committee (Commons)
20th Jul 2015 - 19th Dec 2016
Treasury Committee
8th Jul 2015 - 31st Oct 2016
Treasury Committee
12th Jul 2010 - 30th Mar 2015
Parliamentary Commission on Banking Standards (Joint Committee)
16th Jul 2012 - 12th Jun 2013


Select Committee Meeting
Wednesday 8th December 2021
09:45
International Trade Committee - Oral evidence
Subject: UK-EU trading relationship
8 Dec 2021, 9:45 a.m.
At 10.00am: Oral evidence
Stephen Kelly - CEO at Manufacturing NI
Aodhán Connolly - Director at Northern Ireland Retail Consortium
At 10.45am: Oral evidence
Professor Katy Hayward, Professor of Political Sociology, Queen’s University Belfast - Professor at Queen's University Belfast
Dr Esmond Birnie - Senior Economist at Ulster University
View calendar
Division Votes
Wednesday 1st December 2021
Finance (No. 2) Bill
voted No - in line with the party majority
One of 296 Conservative No votes vs 1 Conservative Aye votes
Tally: Ayes - 215 Noes - 299
Speeches
Friday 19th November 2021
Domestic Building Works (Consumer Protection) Bill

I have privately asked all sorts of senior people and, weirdly, they just roll their eyes and say, “It is …

Written Answers
Monday 25th October 2021
Attorney General: Visits Abroad
To ask the Attorney General, what overseas visits have been made by (a) herself, her predecessor or senior officials in …
Early Day Motions
None available
Bills
Monday 21st June 2021
Domestic Building Works (Consumer Protection) Bill 2021-22
A Bill to make provision about consumer protection in relation to domestic building works; and for connected purposes.
MP Financial Interests
Monday 4th October 2021
7. (i) Shareholdings: over 15% of issued share capital
From 22 September 2021, sole director and shareholder of Kemyel Ltd (dormant), a company set up to manage my financial …

Division Voting information

During the current Parliamentary Session, Mark Garnier has voted in 347 divisions, and 4 times against the majority of their Party.

23 Jun 2020 - Independent Complaints and Grievance Scheme - View Vote Context
Mark Garnier voted Aye - against a party majority and in line with the House
One of 45 Conservative Aye votes vs 235 Conservative No votes
Tally: Ayes - 243 Noes - 238
17 Jun 2020 - Health and Personal Social Services - View Vote Context
Mark Garnier voted Aye - against a party majority and in line with the House
One of 104 Conservative Aye votes vs 124 Conservative No votes
Tally: Ayes - 253 Noes - 136
2 Jun 2020 - Proceedings during the Pandemic - View Vote Context
Mark Garnier voted Aye - against a party majority and against the House
One of 31 Conservative Aye votes vs 240 Conservative No votes
Tally: Ayes - 185 Noes - 242
2 Jun 2020 - Proceedings during the Pandemic - View Vote Context
Mark Garnier voted No - against a party majority and against the House
One of 11 Conservative No votes vs 257 Conservative Aye votes
Tally: Ayes - 261 Noes - 163
View All Mark Garnier Division Votes

Debates during the 2019 Parliament

Speeches made during Parliamentary debates are recorded in Hansard. For ease of browsing we have grouped debates into individual, departmental and legislative categories.

Sparring Partners
Chi Onwurah (Labour)
Shadow Minister (Business, Energy and Industrial Strategy)
(8 debate interactions)
Eleanor Laing (Conservative)
(5 debate interactions)
Nadhim Zahawi (Conservative)
Secretary of State for Education
(5 debate interactions)
View All Sparring Partners
View all Mark Garnier's debates

Latest EDMs signed by Mark Garnier

Mark Garnier has not signed any Early Day Motions

Commons initiatives

These initiatives were driven by Mark Garnier, and are more likely to reflect personal policy preferences.

MPs who are act as Ministers or Shadow Ministers are generally restricted from performing Commons initiatives other than Urgent Questions.


Mark Garnier has not been granted any Urgent Questions

Mark Garnier has not been granted any Adjournment Debates

2 Bills introduced by Mark Garnier


A Bill to make provision about consumer protection in relation to domestic building works; and for connected purposes.


Last Event - 2nd Reading (Commons)
Friday 19th November 2021

A Bill to require that companies selling road fuels be required to charge prices equalised between rural and urban areas; and for connected purposes.


Last Event - 1st Reading: House Of Commons
Tuesday 20th January 2015

Mark Garnier has not co-sponsored any Bills in the current parliamentary sitting


9 Written Questions in the current parliament

(View all written questions)
Written Questions can be tabled by MPs and Lords to request specific information information on the work, policy and activities of a Government Department
15th Oct 2021
To ask the Attorney General, what overseas visits have been made by (a) herself, her predecessor or senior officials in her Department, (b) the Director of Public Prosecutions or senior CPS officials and (c) the Director of the Serious Fraud Office or senior officers over the last 12 months; which countries were visited; what matters were discussed; and whether covid-19 quarantine rules were followed by all people making such visits.

The Attorney General, Solicitor General and senior officials in the department have not undertaken any overseas visits in the last 12 months.

In June 2021, Lisa Osofsky (The Director of the Serious Fraud Office) and John Carroll (Chief Operating Officer of the Serious Fraud Office) visited the United States of America (USA). The purpose of the visit was to meet strategic partners and discuss collaboration and cooperation in tackling serious and complex economic crime. They both followed Covid protocols throughout their time abroad and on returning to the UK.

In October 2021, on a visit to the USA, the Director attended a work meeting with DOJ Senior Officials. In this meeting, she met with American Operational partners and discussed collaboration and cooperation in tackling serious and complex economic crime. The Director followed Covid protocols in place for foreign travel.

No overseas visits have been undertaken by any other Senior SFO Officer over the past 12 months.

Over the past 12 months, the Director of Public Prosecutions completed two overseas business trips, to Poland and the United States. During both visits, the DPP met key stakeholders, including HMG officials. Both of these visits provided an important opportunity to demonstrate support for CPS Liaison Prosecutors based in these jurisdictions and to cement the importance of their role and our cooperation with our international partners.

On both occasions, there were no requirements to quarantine on entry into either country, or on return to the UK.

Alex Chalk
Solicitor General (Attorney General's Office)
22nd Jan 2020
To ask the Secretary of State for Health and Social Care, how many prescriptions for (a) Nabilone Savitex, (b) Epidiolex and (c) unlicensed cannabis-based products for medicinal use were dispensed by hospital pharmacies from November 2018 to October 2019.

The average cost to the National Health Service of all prescriptions for unlicensed cannabis-based products dispensed in the community from November 2018 to October 2019 was £2,789.21 per prescription.

The NHS Business Services Authority does not hold data for prescriptions dispensed by hospital pharmacies, including for Nabilone, Sativex, Epidyolex* and unlicensed cannabis-based products for medicinal use. This information is not held centrally and is not routinely published. Intelligence from NHS England and NHS Improvement Controlled Drugs Accountable Officers is that a low number of patients are receiving prescriptions for cannabis-based products for medicinal use in independent secondary/tertiary care in England. However, this data is not collected nationally or routinely published.

In October 2019, for prescriptions issued by private healthcare specialist prescribers and dispensed in the community, there were no prescriptions for Nabilone, one prescription for Sativex, and 33 prescriptions for unlicensed cannabis-based products.

Finally, there was one prescription for unlicensed cannabis-based products prescribed on the NHS and dispensed in the community in October 2019.

Note:

*Epidyolex was unlicensed prior to September 2019; no NHS prescriptions for Epidyolex have been recorded as submitted to the NHS Business Services Authority at the time of this request. Approximately 185 patients have accessed Epidyolex through the manufacturer’s (GW Pharma) early access programmes, ahead of a licensing decision by the European Medicines Agency.

Jo Churchill
Parliamentary Under-Secretary (Department for Environment, Food and Rural Affairs)
22nd Jan 2020
To ask the Secretary of State for Health and Social Care, what the average cost to the NHS was of prescriptions for unlicensed cannabis-based products for medicinal use from November 2018 to October 2019.

The average cost to the National Health Service of all prescriptions for unlicensed cannabis-based products dispensed in the community from November 2018 to October 2019 was £2,789.21 per prescription.

The NHS Business Services Authority does not hold data for prescriptions dispensed by hospital pharmacies, including for Nabilone, Sativex, Epidyolex* and unlicensed cannabis-based products for medicinal use. This information is not held centrally and is not routinely published. Intelligence from NHS England and NHS Improvement Controlled Drugs Accountable Officers is that a low number of patients are receiving prescriptions for cannabis-based products for medicinal use in independent secondary/tertiary care in England. However, this data is not collected nationally or routinely published.

In October 2019, for prescriptions issued by private healthcare specialist prescribers and dispensed in the community, there were no prescriptions for Nabilone, one prescription for Sativex, and 33 prescriptions for unlicensed cannabis-based products.

Finally, there was one prescription for unlicensed cannabis-based products prescribed on the NHS and dispensed in the community in October 2019.

Note:

*Epidyolex was unlicensed prior to September 2019; no NHS prescriptions for Epidyolex have been recorded as submitted to the NHS Business Services Authority at the time of this request. Approximately 185 patients have accessed Epidyolex through the manufacturer’s (GW Pharma) early access programmes, ahead of a licensing decision by the European Medicines Agency.

Jo Churchill
Parliamentary Under-Secretary (Department for Environment, Food and Rural Affairs)
22nd Jan 2020
To ask the Secretary of State for Health and Social Care, how many prescriptions for (a) Nabilone, (b) Savitex and (c) unlicensed cannabis-based products for medicinal use were issued by private healthcare specialist prescribers and dispensed in the community in October 2019.

The average cost to the National Health Service of all prescriptions for unlicensed cannabis-based products dispensed in the community from November 2018 to October 2019 was £2,789.21 per prescription.

The NHS Business Services Authority does not hold data for prescriptions dispensed by hospital pharmacies, including for Nabilone, Sativex, Epidyolex* and unlicensed cannabis-based products for medicinal use. This information is not held centrally and is not routinely published. Intelligence from NHS England and NHS Improvement Controlled Drugs Accountable Officers is that a low number of patients are receiving prescriptions for cannabis-based products for medicinal use in independent secondary/tertiary care in England. However, this data is not collected nationally or routinely published.

In October 2019, for prescriptions issued by private healthcare specialist prescribers and dispensed in the community, there were no prescriptions for Nabilone, one prescription for Sativex, and 33 prescriptions for unlicensed cannabis-based products.

Finally, there was one prescription for unlicensed cannabis-based products prescribed on the NHS and dispensed in the community in October 2019.

Note:

*Epidyolex was unlicensed prior to September 2019; no NHS prescriptions for Epidyolex have been recorded as submitted to the NHS Business Services Authority at the time of this request. Approximately 185 patients have accessed Epidyolex through the manufacturer’s (GW Pharma) early access programmes, ahead of a licensing decision by the European Medicines Agency.

Jo Churchill
Parliamentary Under-Secretary (Department for Environment, Food and Rural Affairs)
22nd Jan 2020
To ask the Secretary of State for Health and Social Care, how many prescriptions for unlicensed cannabis-based products for medicinal use were prescribed by the NHS and dispensed in the community in October 2019.

The average cost to the National Health Service of all prescriptions for unlicensed cannabis-based products dispensed in the community from November 2018 to October 2019 was £2,789.21 per prescription.

The NHS Business Services Authority does not hold data for prescriptions dispensed by hospital pharmacies, including for Nabilone, Sativex, Epidyolex* and unlicensed cannabis-based products for medicinal use. This information is not held centrally and is not routinely published. Intelligence from NHS England and NHS Improvement Controlled Drugs Accountable Officers is that a low number of patients are receiving prescriptions for cannabis-based products for medicinal use in independent secondary/tertiary care in England. However, this data is not collected nationally or routinely published.

In October 2019, for prescriptions issued by private healthcare specialist prescribers and dispensed in the community, there were no prescriptions for Nabilone, one prescription for Sativex, and 33 prescriptions for unlicensed cannabis-based products.

Finally, there was one prescription for unlicensed cannabis-based products prescribed on the NHS and dispensed in the community in October 2019.

Note:

*Epidyolex was unlicensed prior to September 2019; no NHS prescriptions for Epidyolex have been recorded as submitted to the NHS Business Services Authority at the time of this request. Approximately 185 patients have accessed Epidyolex through the manufacturer’s (GW Pharma) early access programmes, ahead of a licensing decision by the European Medicines Agency.

Jo Churchill
Parliamentary Under-Secretary (Department for Environment, Food and Rural Affairs)
15th Oct 2021
To ask the Secretary of State for Foreign, Commonwealth and Development Affairs, whether her Department has given consular assistance to the (a) Director of Public Prosecutions or senior CPS officials and (b) Director of the Serious Fraud Office or senior SFO officials in support of any investigations being undertaken by those offices in the last 12 months.

The FCDO provides consular assistance to British Nationals overseas on a case by case basis. We keep and use information in line with the Data Protection Act 2018. We cooperate with other government departments and public authorities - including the Crown Prosecution Service (CPS) and the Serious Fraud Office (SFO) - in relation to those cases where necessary and may release information to them in accordance with relevant exemptions. More information on consular assistance can be found in the publicly available document "Support for British Nationals Abroad - A Guide" (https://www.gov.uk/government/publications/support-for-british-nationals-abroad-a-guide) and on how personal data is stored and processed in our consular privacy notice: (https://www.gov.uk/government/publications/fcdo-privacy-notice-consular-services-in-the-uk-and-at-british-embassies-high-commissions-and-consulates-overseas).

Amanda Milling
Minister of State (Foreign, Commonwealth and Development Office)
24th Jun 2020
To ask the Secretary of State for the Home Department, with reference to the judicial reviews brought by Hereford and Worcester Fire Authority and Shropshire Fire and Rescue Authority against their proposed merger, what steps she is taking to ensure that legal processes do not prevent the delivery of future efficient and safe mergers.

In March 2020, the Court of Appeal refused permission for the FRAs in West Mercia to appeal the High Court’s judgment on the transfer of fire governance to the PCC for West Mercia, bringing to end the judicial review. Further JR proceedings have now become redundant in light of current developments.

It is disappointing that lengthy legal action by the FRAs in West Mercia has meant that we have not yet been able to implement a transfer of governance that we considered to be in the interest of the local community.

We remain strongly committed to supporting PCCs to take on fire governance where a case exists, and I look forward to reviewing any updated proposal the newly elected PCC may decide to bring forward after the elections. We will be working with the sector in the meantime to consider the lessons learned from this process.

Kit Malthouse
Minister of State (Ministry of Justice) (jointly with Home Office)
23rd Jun 2020
To ask the Secretary of State for the Home Department, what recent assessment she has made of the potential merits of not proceeding with the proposed merger of West Mercia Police Authority with Hereford and Worcester Fire Authority and Shropshire Fire and Rescue Authority.

In July 2019, the High Court upheld the then Home Secretary’s (Amber Rudd MP) decision of March 2018 to transfer governance of Hereford and Worcester and Shropshire and Wrekin Fire and Rescue Service to the PCC for West Mercia. The Court of appeal has refused permission for the FRAs to appeal the judgement

However, given the time that has passed and developments since the business case was originally submitted in October 2017, it is right that we reconsider whether the case still meets the statutory tests. The Minister for Crime and Policing has written to PCC John Campion to explain that we will require an updated business case.

It is for the PCC and Fire and Rescue Authorities to consider whether to publish information they hold relating to the proposal, although I am aware that some of this is currently available through their websites.

Kit Malthouse
Minister of State (Ministry of Justice) (jointly with Home Office)
23rd Jun 2020
To ask the Secretary of State for the Home Department, what steps she is taking to ensure that that the parties involved in the merger of the West Mercia Police Authority with Hereford and Worcester Fire Authority and Shropshire Fire and Rescue Authority publish the (a) advice and (b) resources they provided to determine the potential merits of the merger.

In July 2019, the High Court upheld the then Home Secretary’s (Amber Rudd MP) decision of March 2018 to transfer governance of Hereford and Worcester and Shropshire and Wrekin Fire and Rescue Service to the PCC for West Mercia. The Court of appeal has refused permission for the FRAs to appeal the judgement

However, given the time that has passed and developments since the business case was originally submitted in October 2017, it is right that we reconsider whether the case still meets the statutory tests. The Minister for Crime and Policing has written to PCC John Campion to explain that we will require an updated business case.

It is for the PCC and Fire and Rescue Authorities to consider whether to publish information they hold relating to the proposal, although I am aware that some of this is currently available through their websites.

Kit Malthouse
Minister of State (Ministry of Justice) (jointly with Home Office)